Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (Diluted Average): 2014-2024

Historic Shares Outstanding (Diluted Average) for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Dec 2024 value amounting to $200.2 million.

  • Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) rose 21.19% to $228.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.9 million, marking a year-over-year increase of 21.19%. This contributed to the annual value of $200.2 million for FY2024, which is 15.94% up from last year.
  • Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) amounted to $200.2 million in FY2024, which was up 15.94% from $172.7 million recorded in FY2023.
  • Lineage Cell Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $200.2 million during FY2024, with a 5-year trough of $169.8 million in FY2022.
  • For the 3-year period, Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) averaged around $180.9 million, with its median value being $172.7 million (2023).
  • Data for Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY rose of 15.94% (in 2024) over the last 5 years.
  • Over the past 3 years, Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $169.8 million in 2022, then increased by 1.69% to $172.7 million in 2023, then climbed by 15.94% to $200.2 million in 2024.